Signal mining and analysis of adverse drug events of tirzepatide

XIE Zeyu; LIANG Zhuoru; ZHENG Guimei; CAO Weiling; CHEN Jisheng

doi:10.6039/j.issn.1001-0408.2025.08.11

您当前的位置：

首页 >

文章列表页 >

Signal mining and analysis of adverse drug events of tirzepatide

更新时间：2025-09-23

- Signal mining and analysis of adverse drug events of tirzepatide
- ZHONGGUO YAOFANG Vol. 36, Issue 8, Pages: 956-960(2025)
- 作者机构：
  
  1.深圳市罗湖区人民医院药学部，广东深圳　518000
  2.广东药科大学附属第一医院国家临床药学重点专科，广州　510080
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.08.11
  CLC： R969.3;R587
- Received：14 October 2024，
  
  Revised：2024-11-13，
  
  Accepted：12 March 2025，
  
  Published：30 April 2025
- 稿件说明：
移动端阅览
谢泽宇,梁焯茹,郑桂梅,等.替尔泊肽不良事件信号挖掘与分析 [J].中国药房,2025,36(08):956-960.

XIE Zeyu,LIANG Zhuoru,ZHENG Guimei,et al.Signal mining and analysis of adverse drug events of tirzepatide[J].ZHONGGUO YAOFANG,2025,36(08):956-960.
谢泽宇,梁焯茹,郑桂梅,等.替尔泊肽不良事件信号挖掘与分析 [J].中国药房,2025,36(08):956-960. DOI： 10.6039/j.issn.1001-0408.2025.08.11.

XIE Zeyu,LIANG Zhuoru,ZHENG Guimei,et al.Signal mining and analysis of adverse drug events of tirzepatide[J].ZHONGGUO YAOFANG,2025,36(08):956-960. DOI： 10.6039/j.issn.1001-0408.2025.08.11.

摘要

目的

基于FDA不良事件报告系统（FAERS）数据库，对替尔泊肽相关药物不良事件（ADE）信号进行挖掘分析，为临床安全用药提供参考。

方法

通过FAERS数据库提取2022年5月1日至2024年6月30日替尔泊肽为首要怀疑药物的ADE报告，并利用《国际医学用语词典》对筛选后的ADE的系统器官分类（SOC）和首选术语进行系统归纳，再通过报告比值比法和比例报告比值法对上述ADE进行信号挖掘及分析。

结果

共获得替尔泊肽相关ADE报告39 229份，严重ADE报告3 934份（10.03%），严重的ADE报告以导致住院/住院时间延长为主（3.82%），涉及131个ADE阳性信号；已报告患者性别和患者年龄的ADE报告中，女性26 195份（66.77%），男性7 869份（20.06%），年龄以18～64岁为主（54.26%）。发生频次排名前3位的ADE分别为注射部位疼痛、恶心和注射部位出血。信号较强且并未被替尔泊肽说明书提及的ADE分别为注射部位发凉、饥饿性酮症酸中毒、注射部位出血、饥饿、肾上腺素升高、注射部位皮肤开裂、贪食、皮肤松解、肠脓毒症、饱腹感缺乏和痛觉异常。患者性别和年龄亚组分析结果表明，不同性别和年龄段患者的ADE报告数在不同SOC下所占比例存在差异，男性或≥65岁患者在胃肠系统疾病的风险大于女性或＜65岁患者。

结论

临床应用替尔泊肽时，除了关注药品说明书中记载的ADE外，还应关注注射部位发凉、饥饿性酮症酸中毒、注射部位出血、肾上腺素升高、肠脓毒症等药品说明书未提及的ADE，以保障患者安全用药。

Abstract

OBJECTIVE

To identify and analyze adverse drug event （ADE） signals associated with tirzepatide based on the FDA Adverse Event Reporting System （FAERS） database， providing a reference for clinical medication safety.

METHODS

ADE reports from January 1， 2022， to June 30， 2024， with tirzepatide as the primary suspected drug， were extracted from the FAERS database.

Medical Dictionary for Regulatory Activities

was used to systematically categorize the selected system organ class （SOC） and preferred term of ADE. Signal mining and analysis were performed using the reporting odds ratio method and the proportional reporting ratio method.

RESULTS

A total of 39 229 ADE reports related to tirzepatide were obtained， including 3 934 severe ADE reports （10.03%）. The majority of severe ADE reports were related to hospitalization or prolonged hospitalization （3.82%）， involving 131 positive ADE signals. Among the reports with documented patient gender and age， 26 195 were female （66.77%）， 7 869 were male （20.06%）， and the majority of patients were aged 18-64 years （54.26%）. The top three most frequently reported ADE were injection site pain， nausea， and injection site hemorrhage. Strong ADE signals not mentioned in the tirzepatide instruction included injection site coldness， starvation ketoacidosis， injection site hemorrhage， hunger， elevated adrenaline， injection site skin cracking， binge eating， skin laxity， intestinal sepsis， lack of satiety， and dysesthesia. Subgroup analysis for patient’s gender and age showed differences in the proportion of ADE reports across different SOC. Male patients or those aged≥65 years had a higher risk of gastrointestinal system disorders compared to female patients or those aged ＜65 years.

CONCLUSIONS

In clinical use of tirzepatide， in addition to monitoring ADE listed in the instruction， attention should also be paid to ADE not mentioned in the instruction， such as injection site coldness， starvation ketoacidosis， injection site hemorrhage， elevated adrenaline， and intestinal sepsis， to ensure patient safety.

关键词

Keywords

references

LIU J L ， LIU M ， CHAI Z L ， et al . Projected rapid growth in diabetes disease burden and economic burden in China：a spatio-temporal study from 2020 to 2030 [J ] . Lancet Reg Health West Pac ， 2023 ， 33 ： 100700 .

张文竹，周扬，石杰 . 首个治疗2型糖尿病的GIP和GLP-1双重受体激动剂：替尔泊肽 [J ] . 中国新药与临床杂志， 2023 ， 42 （ 10 ）： 630 - 634 .

郑彩云，林妹妹，戴亨纷 . GLP-1受体激动剂致2型糖尿病患者胃肠道不良反应的网状Meta分析 [J ] . 中国新药与临床杂志， 2024 ， 43 （ 6 ）： 460 - 468 .

XIE Z Y ， ZHENG G M ， LIANG Z R ， et al . Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight：an updated systematic review and network meta-analysis of randomized controlled trials [J ] . Metabolism ， 2024 ， 161 ： 156038 .

XIE Z Y ， HU J ， GU H Y ， et al . Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes：a systematic review [J ] . Front Endocrinol（Lausanne）， 2023 ， 14 ： 1244432 .

ELSAYED N A ， ALEPPO G ， ARODA V R ， et al . Pharmacologic approaches to glycemic treatment：standards of care in diabetes：2023 [J ] . Diabetes Care ， 2023 ， 46 （ Suppl. 1 ）： S140 - S157 .

ZHANG X Y ， HAMADEH I S ， SONG S ， et al . Osteonec-rosis of the jaw in the United States Food and Drug Administration’s Adverse Event Reporting System（FAERS） [J ] . J Bone Miner Res ， 2016 ， 31 （ 2 ）： 336 - 340 .

HAUBEN M ， HORN S ， REICH L . Potential use of data-mining algorithms for the detection of ‘surprise’ adverse drug reactions [J ] . Drug Saf ， 2007 ， 30 （ 2 ）： 143 - 155 .

王盼，朱文涛，郭国富，等 . 药品不良反应信号检测研究现状 [J ] . 中国药房， 2013 ， 24 （ 2 ）： 97 - 100 .

周瑞珊，卢佩雯，陈君恒，等 . 药品不良反应数据挖掘技术在药物警戒中的应用 [J ] . 中国现代应用药学， 2024 ， 41 （ 6 ）： 864 - 870 .

KAUTZKY-WILLER A ， LEUTNER M ， HARREITER J . Sex differences in type 2 diabetes [J ] . Diabetologia ， 2023 ， 66 （ 6 ）： 986 - 1002 .

RENTZEPERI E ， PEGIOU S ， KOUFAKIS T ， et al . Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists：opportunities for a tailored approach to diabetes and obesity care [J ] . J Pers Med ， 2022 ， 12 （ 3 ）： 454 .

卢伟涛，何家汝，陈文瑛 . 基于FAERS数据库的司美格鲁肽药品不良事件信号挖掘 [J ] . 中国药房， 2022 ， 33 （ 15 ）： 1865 - 1869，1875 .

MIZUMOTO J . Tirzepatide-induced injection site reaction [J ] . Cureus ， 2023 ， 15 （ 9 ）： e45181 .

CARUSO I ， DI GIOIA L ， DI MOLFETTA S ， et al . The real-world safety profile of tirzepatide：pharmacovigilance analysis of the FDA Adverse Event Reporting System（FAERS）database [J ] . J Endocrinol Invest ， 2024 ， 47 （ 11 ）： 2671 - 2678 .

LIU L Y . A real-world data analysis of tirzepatide in the FDA Adverse Event Reporting System（FAERS）database [J ] . Front Pharmacol ， 2024 ， 15 ： 1397029 .

HUO Y ， MA M H ， LIAO X L . Data mining study on adverse events of tirzepatide based on FAERS database [J ] . Expert Opin Drug Saf ， 2024 ： 1 - 9 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mining and analysis of lorlatinib-induced adverse drug event signals

Mining and analysis of adverse drug event signals of lacosamide

Signal mining and analysis of adverse drug event signals of darolutamide

Data mining and analysis of oxaliplatin-related adverse events of nervous system

Risk signal mining of ixazomib based on the database of FAERS

Related Author

ZHOU Houfeng

TANG Mengjiao

WANG Lichen

PU Shiyun

HUANG Mengwen

LONG Xia

LOU Yuefen

XU Ni

Related Institution

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

School of Pharmacy，Chengdu University of Traditional Chinese Medicine

College of Pharmacy， North Sichuan Medical College， Sichuan Nanchong

College of Pharmacy，Southwest Medical University

Dept. of Pharmacy， Shanghai Fourth People’s Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰